Trial Profile

EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cinacalcet (Primary)
Indications Cardiovascular disorders; Heart failure; Myocardial infarction; Secondary hyperparathyroidism
Focus Registrational; Therapeutic Use
Acronyms EVOLVE
Sponsors Amgen

Most Recent Events

29 Sep 2022 Results (n=2751) of post hoc analysis assessing effect of cinacalcet treatment on SHBG, free or total testosterone published in the Nephrology Dialysis Transplantation
08 Feb 2022 According to an Oculis Pharma media release, Dr. Bastian Dehmel led this study.
15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com